DMSO =102mg/mL, Water <1.2mg/mL, Ethanol =2.9mg/mL
Application(s):
Cathepsin K
Form:
Free Base
Research Area:
Neurological disease
REVIEW Odanacatib (MK 0822) is an inhibitor of cathepsin K with potential anti-osteoporotic activity. Odanacatib selectively binds to and inhibits the activity of cathepsin K (IC50=0.2nM), which may result in a reduction in bone resorption, improvement of bone mineral density, and a reversal in osteoporotic changes. Odanacatib is currently in clinical development for the treatment of postmenopausal osteoporosis.
REFERENCES
[1]
Sun L, Forni S, Schwartz MS, Breidinger S, Woolf EJ.Quantitative determination of odanacatib in human plasma using liquid-liquid extraction followed by liquid chromatography-tandem mass spectrometry analysis.J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Feb 15;885-886:15-23. Epub 2011 Dec 13.
[2]
Khosla S.Odanacatib: location and timing are everything.J Bone Miner Res. 2012 Mar;27(3):506-8.
[3]
Langdahl B, Binkley N, Bone H, Gilchrist N, Resch H, Portales JR, Denker A, Lombardi A, De Tilleghem CL, Dasilva C, Rosenberg E, Leung A.Odanacatib in the treatment of postmenopausal women with low bone mineral density: 5 years of continued therapy in a phase 2 study.J Bone Miner Res. 2012 Jul 6.
[4]
Ng KW.Potential role of odanacatib in the treatment of osteoporosis.Clin Interv Aging. 2012;7:235-47. Epub 2012 Jul 12.
All in-stock products are shipped from San Francisco Bay Area, California, USA.
⚠️
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.
Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.